Navigation Links
New Report Illuminates Ampligen's Unique Mechanism of Action

PHILADELPHIA--(BUSINESS WIRE)--Apr 30, 2007 - Hemispherx Biopharma, Inc. (AMEX: HEB) announced today the first scientific publication (Journal of Immunology, April 2007) that explains the unique therapeutic properties of its proprietary experimental therapeutic, Ampligen(R) (Poly I : Poly C(12)U), a double-stranded RNA being tested as a monotherapy for Chronic Fatigue Syndrome and as an adjuvant to other drugs and vaccines.

The new peer-reviewed study shows conclusively that the biologic properties of Ampligen(R) are conveyed exclusively by a unique naturally occurring receptor on the cell surface called "TLR-3." Toll-like receptors or "TLRs" such as TLR-3 serve as "pattern recognition" receptors in the early detection of pathogens and the establishment of early defense mechanisms (innate immunity). As such, they are critical to the first line of immunological defense against a broad range of pathogens, such as otherwise lethal viruses and even various forms of cancer.

When the dormant alarm signals of TLRs are activated (as by exposure to a pathogen or a stimulant agent such as Ampligen(R)), TLRs in effect cause an overreaction, driving the body to proliferate broad-spectrum defenses against many types of pathogens.

New research shows that these receptors present in virtually all life forms, from mosquitoes to man (in scientific terms, they are remarkably "evolutionarily conserved"). This suggests that TLRs are critical to retaining healthy life in a constantly changing environment full of hostile pathogens, many of which the subject has never encountered before.

The study was conducted in TLR-3 "knockout" animals at Utah State University under a NIH contract and with the aid of a variety of collaborators representing a consortium of institutions (Yale University, Vanderbilt University, and the Centre d'Immunologie de Marseille-Luminy), to determine if TLR-3 is essential for the activities of dsRNAs for the induction of innate immunity. Unlike the toxic Poly I:Poly C, Ampligen is directed towards the activation of TLR-3 in the induction of innate immune responses.

The closely allied compound, Poly I : Poly C, has been used in clinical trials but has a broad range of side-effects, some of which are life-threatening. Where the studies found specific involvement of TLR-3 in conveying Ampligen(R)'s biologic properties, no such specificity was seen with poly I : poly C, thus explaining its side effect profile without compromising its potency as an immunotherapeutic.

The findings further establish the remarkable specificity of Ampligen(R) in activating the critical first line of defense against various types of pathogenic elements. The findings are pertinent to many cutting edge therapeutic topics in biotechnology today, including the enhancement of vaccine efficacy (both antiviral and anticancer) as well as strengthening biologic therapy (interferons, interleukins, etc.) of various serious human diseases as well as enhancing traditional antivirals such as Tamiflu(R) and Relenza(R).

The experimental therapeutic Ampligen(R) is perhaps the best studied TLR activator in human clinical trials to date, having been administered more than 75,000 times in approximately 15 clinical trials of which four were very well-controlled (placebo-controlled, randomized, multi-center, double-blinded).

"These scientific findings go a long way toward explaining how a single, relatively simple compound, Ampligen(R), can repeatedly show therapeutic promise in such a broad array of indications. The findings may also have broad economic implications for the American biotechnology sector," commented Dr. William A. Carter, Chairman and CEO of Hemispherx Biopharama, Inc. "According to a recent KPMG Bioscience report, our sector recently achieved a new high of $70 billion in revenues a year, but is now faced with many very short product life cycles, large po rtfolios of expiring patents and the corresponding potential for global generic competition. However, specific TLR promoters, such as Ampligen(R), may have the potential to increase the efficacy of a broadly diverse set of previously licensed biological products, thus effectively extending their useful commercial life cycles." Hemispherx has a set of patent applications pending worldwide related to safely enhancing the therapeutic responses of biological products.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) and the experimental therapeutics Ampligen(R) and Oragens(R). Alferon N Injection(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(R) represent experimental RNA nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigat ional drugs and associated technologies of the Company (including Ampligen(R), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.

NOTE TO EDITORS: In the expression Poly C(12)U, which appears in the first paragraph, the "12" is a subscript. This placement may not appear properly in some systems.

Contact

Hemispherx Biopharma, Inc.
Dianne Will, 518-398-6222
ir@hemispherx.net
or
CCG Investor Relations
Sean Collins, Sr. Partner, 310-477-9800


'"/>




Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... ... the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm ... Dr. Maisel, founder of Retina Group of New York , is a ...
(Date:5/26/2016)... Los Angeles, CA (PRWEB) , ... May 26, 2016 , ... In an effort to ... Snapchat videos available to both Snapchat users and those who do not use the app. ... available on his new page, Dr. Mohebi Live . , Dr. Mohebi says, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science Logistics ... organization has earned its ISO 13485 certification, indicating the company’s quality control system ... and policies associated with ISO quality standard 13485. , BSI Group America, ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute ... a six-week smoking cessation class starting June 6 at their clinic in downtown Tampa. ... . , Additionally, the Lung Institute has created a free downloadable 4 Week ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at East ... practices, arts & crafts, discussions, and games all geared towards enhancing your child’s ... combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga training. ...
Breaking Medicine News(10 mins):